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Monoclonal antibodies (mAbs) are a group of antibodies produced by identical 
clones of B lymphocytes against a particular antigen. mAbs are identical in several 
properties such as protein sequence, antigen-binding site region, binding affinity 
for their targets, and identical downstream functional effects. These characteristics 
of mAbs highlight their differences with the polyclonal antibodies which have het-
erogenous activities and recognize different epitopes on an antigen. Murine mAbs 
was the first generation of mAbs developed by hybridoma technology however, 
because of their murine origin, they can trigger the anti-mouse antibody response 
in the host which could accelerate mAb clearance and undesirable allergic reactions 
upon repeated administration. This issue was resolved by developing engineering 
methods toward producing less immunologic chimeric or humanized antibod-
ies. mAbs applications have become a novel way of targeting antigens in a wide 
variety of diseases such as autoimmunity, malignancies, and asthma. In addition, 
high specificity and high affinity binding properties of mAbs make them effective 
biological reagents in immunodiagnostic assays. They can be used in diagnosis of 
infectious diseases and detection of certain antigens or in serological assessments 
for detection of antibodies against a certain antigen. This chapter summarizes 
the general properties of mAbs, their production processes, and their important 
diagnostic and therapeutic applications.
Keywords: monoclonal antibodies, mAb, chimeric mAb, humanized mAb,  
fully humanized mAb
1. Introduction
Antibodies or immunoglobulins (Ig) are glycoproteins produced by differenti-
ated B lymphocytes named “plasma cells” in response to exposure to antigens. The 
diversity of antibody responses to different antigens is because of the gene recom-
bination process in the hyper-variable regions of antibodies. During the recombi-
nation process in their genes, antibodies undergo gene rearrangement that allows 
them for diverse binding [1]. High specificity and diversity of antibodies have 
made them popular molecules with very high efficiencies in several therapeutic or 
diagnostic applications.
Monoclonal antibodies (mAbs) are a group of antibodies produced by identi-
cal clones of B lymphocytes against a particular antigen. Monoclonal antibodies 
are identical in several properties such as protein sequence, antigen-binding 
site region, binding affinity for their targets, and identical downstream func-
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Different types of monoclonal antibodies. Murine mAbs were the first generation of mAbs with higher 
immunogenicity in humans. Gene engineering methods provide the less immunogenic mAbs by replacing 
human components in mAb structure. mAb: Monoclonal antibody.
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polyclonal antibodies which have heterogenous activities and recognize different 
epitopes on an antigen.
Using mAbs has become a novel way of targeting antigens in a wide variety 
of diseases and conditions since the first mAb was approved in 1986. Orthoclone 
OKT3® (muromonab-CD3) was the first mAb approved by the Food and Drug 
Administration (FDA). OKT3 was produced based on murine hybridoma technology 
by Kohler and Milston for the treatment of acute transplant rejection [2]. Currently, 
mAbs are the important group of therapeutic molecules in clinical trials for treating 
different disorders such as inflammatory and autoimmune diseases (e.g. rheumatoid 
arthritis, systemic lupus erythematosus, psoriasis, inflammatory bowel diseases), 
malignancies (e.g. leukemia, melanoma, breast cancer, and multiple myeloma), 
cardiovascular, and infectious diseases [3].
Murine mAbs was the first generation of monoclonal antibodies developed 
by hybridoma technology. They have no human components in their structure 
and could result in producing human anti-mouse antibodies (HAMAs). HAMA 
response caused hypersensitivity reactions (e.g. anaphylaxis and serum sickness) 
in the recipients, resulting in fast clearance of antibodies or reducing their effec-
tiveness [4]. Genetic engineering approaches and using transgenic animals were 
developed to overcome these troubles; So that a transformed cell line could produce 
the altered antibody structurally closer to human antibodies. These modified 
antibodies are known as chimeric mAbs because their constant region is human 
while their variable region is murine (Table 1). This technology was developed for 
the first time in 1980s by scientists in Cambridge, UK. After that, humanized and 
fully human mAbs were developed to reduce mAb immunogenicity and their side 
effects. Humanized antibodies have human light and heavy chains but hypervari-
able regions are still murine while fully human antibodies are totally humanized. 
However, they are still immunogens and may have important adverse effects 
caused by production of antidrug antibodies (ADAs) [5]. This chapter summarizes 
the general properties of mAbs, their production processes, and their important 
applications, including therapeutic and diagnostic uses.
2.  Antibody structure and functions: immunoglobulin G as the 
therapeutic mAb
An antibody molecule has a Y-shaped structure with a total molecular weight of 
~150 kDa, composed of four polypeptide chains including two identical heavy (H) 
and two light (L) chains (Figure 1). Covalent bonds (mainly disulfide interactions) 
provide the stability of heavy and light chains next to each other. Each heavy or light 
chain is composed of constant (CH and CL, respectively) and variable domains 
(VH and VL, respectively) [4].
Each antibody has two identical arms known as “antigen binding fragments” or 
Fabs, acting as antigen-binding sites. Each Fab consists of a variable region known 
as Fv (formed by the VH and VL domains), and the constant region (formed by 
the CH and CL domains). Fv is a highly variable region and responsible for specific 
binding of antibody to the antigen, contributing to direct effects of antibody such 
as inhibiting or neutralizing the antigen. There are three hyper variable regions 
known as complementarity determining regions or CDR1, CDR2, and CDR3 in the 
variable regions of light and heavy chains, allowing diverse antigenic specificities 
to be recognized [4]. The Y structure’s stem, known as the “fragment crystallizable 
region” or Fc, is a constant region of the antibody molecule. The Fc region deter-
mines the class of the antibody and its functional properties. There are five classes 
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of antibodies including immunoglobulin G (IgG), IgM, IgD, IgE, and IgA with 
distinct effector mechanisms for recognition and elimination of the antigens. In 
addition, the Fc region can interact with a variety of receptors such as Fc receptors 
or FcRs (expressed on the immune cells) and the components of the complement 
system (such as C1q). Fc recognition by the immune system components results 
in initiating the effector functions of antibodies such as antibody-dependent cell 
cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and 
complement-dependent cytotoxicity (CDC) (Figure 2) [4].
Therefore, several functions are explained by which antibodies can elimi-
nate a particular antigen and both variable and constant regions of antibodies 
contribute to this response. The stability and flexibility of antibodies and their 
effector functions such as activating ADCC, CDC, as well as interaction with C1q 
are important factors determining the suitability of immunoglobulins for the 
development of therapeutic mAbs. The majority of the clinically available mAbs 
are IgG. IgG is a glycoprotein with a size of 150 kDa consisting of two heavy and 
two light chains as described before. A conserved glycosylation site is present at 
amino acid Arginine297 (N297) in the CH2 domain, playing an important role in 
the structural conformation of the Fc and its binding to FcRs and complement 
component C1q [6].
Totally, IgG consists of four subclasses of IgG1, IgG2, IgG3 and IgG4 which 
differ in their heavy constant region (CH), as well as the hinge structure (the region 
where Fabs are bound to the Fc region). The difference between hinge regions con-
fers many of the unique characteristics to each IgG subclass, including flexibility, 
stability and distances between the two Fabs. In addition, the amino acid differ-
ences between the binding sites of each subclass could explain the differences in the 
Figure 1. 
The schematic structure of an antibody. An antibody molecule is composed of four polypeptide chains including 
two identical heavy (H) and two light (L) chains. Each heavy or light chain is composed of constant (CH and 
CL, respectively) and variable domains (VH and VL, respectively). Variable domains form the antigen binding 
site. CDR: complementarity determining regions; S-S: disulfide bond; C: constant; V: variable.
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effector functions of the IgG subclasses. These variations between IgG subclasses 
correlate with their selection for therapeutic purposes. Of the IgG subclasses, IgG3 
has a longer hinge region compared with other subclasses, making them inappropri-
ate for target binding. On the other hand, IgG3 cannot be purified with protein A 
and also has the shortest half-life (approximately 7 days) and high allotypic poly-
morphism compared with other subclasses. So, engineering techniques are required 
for modifications to the amino acid content of the IgG3 hinge region for develop-
ment of therapeutics purposes. Meanwhile, most of the mAb therapeutics on the 
market are composed of IgG1, IgG2 or IgG4 with slow clearance and long half-life 
properties [6, 7].
IgG1 has high stability and exhibits potent effector functions including ADCC, 
CDC, and C1q binding being the majority of therapeutic mAbs. IgG1 has the higher 
affinity for the FcRs compared with the other subclasses (the affinity for Fc receptor: 
IgG1 > IgG3 > IgG4 > IgG2 respectively) [6].
IgG2 has low affinity for interaction with antigen and also exhibits reduced 
functional activity compared to IgG1. IgG2 antibodies have three isoforms (known 
as IgG2-A, IgG2-A/B, and IgG2-B) based on types of disulfide bonds between the 
antibody chains. These isoforms could be converted to each other. This phenom-
enon, which is referred to disulfide shuffling, could regulate the activity of IgG2 in 
the serum [8, 9].
IgG4 has a low affinity for C1q and therefore, this subclass of IgG could emerge 
as a therapeutic mAb when the host effector function is not desirable. In addition, 
the exchange of Fab arm is a normal biological process that can occur in IgG4 and 
is not desirable due to its adverse effects. Natalizumab (Tysabri) and gemtuzumab 
ozogamicin (Mylotarg) are the examples of therapeutic IgG4 for multiple sclerosis 
(MS) and acute myeloid leukemia (AML), respectively [6].
3. The production process of monoclonal antibodies
In the following section we described two techniques, including hybridoma and 
phage display used for the production of mAbs.
Figure 2. 
Two important effector functions of antibody. ADCC is an extracellular killing mechanism leading to antigen 
elimination. IgG has a bifunctional structure related to the fragment antigen-binding (fab) and fc portions of 
antibody. ADCC is initiated by the engagement of fab with the antigen from one side, and fc interaction with 
FcγR on effector cells, from another site. Subsequently, degranulation of effector cells (mainly NK cells) leads 





Monoclonal antibodies are generated from a single B lymphocyte clone and bind 
to the same epitope of an antigen. The hybridoma technique was first used in 1975 
to generate mAbs by Milstein and Köhler. Several steps are involved in this method. 
First, mice are immunized with specific antigens emulsified with appropriate 
adjuvant. The booster injection is normally done after two weeks and the animal 
is then sacrificed when enough amount of antibody is produced. Blood collection 
is performed to assay the sufficient amount of the antibody production using 
techniques including ELISA and flow cytometry. After sacrificing, the spleen is 
isolated and then tissue digestion could be applied with an enzymatic or mechanical 
method leading to release of B cells. B cells could be extracted using density gradi-
ent centrifugation [8].
The next step is making a fusion between B lymphocytes and myeloma cells 
(that are immortal like cancer cells). Prior to fusion, myeloma cells should be pre-
pared by culturing with 8 – azaguanine, making them sensitive to hypoxanthine-
aminopterin-thymidin (HAT) medium. The fusion process is carried through using 
polyethylene glycol (PEG), resulting in cell membrane fusing. After the fusing 
process, there will be a variety of cells including fused B cells with myeloma cells, 
unfused B cells, unfused myeloma cells, B cells fused to B cells, myeloma cells 
fused to myeloma cells. Therefore, a selective medium known as hypoxanthine, 
aminopterin and thymidine (HAT) medium should be used to select only the B cells 
fused with myeloma cells [10]. Two components of this medium, hypoxanthine 
and thymidine, are the metabolites of the salvage pathway of nucleoside synthesis. 
Therefore, only the cells that have the necessary enzyme for the salvage synthesis of 
nucleic acids, named hypoxanthine-guanine-phosphoribosyl transferase (HGPRT), 
will be able to survive. Unfused myeloma cells lack HGPRT, so they cannot replicate 
their nucleic acid and they will not be able to grow in HAT medium. On the other 
hand, unfused B cells have a limited life span and therefore cannot grow appropri-
ately. Consequently, only fused B cell-myeloma cells known as “hybridomas” are 
able to grow in the medium. It should be noted that another pathway of nucleic acid 
synthesis named “de novo” pathway, is also inhibited due to the presence of ami-
nopterin in HAT medium. So, only the HGPRT-positive cells could be grown in this 
selective medium [8, 10].
To separate antibodies with different specificity and also for further hybridoma 
growth, the mixture of cells is diluted in microtiter wells in which their walls are 
coated with murine macrophages or feeder fibrocyte cells providing the growth 
factors needed for antibody-producing cells. Then, the antigen-binding ability of 
secreted antibodies by different clones of B cells could be assessed by ELISA, anti-
gen microarray assay, radio-immuno assay (RIA), or immune-dot blot and finally, 
the stable clone will be selected. The fused hybridomas and produced mAbs can be 
stored away in liquid nitrogen [8].
Although this process may be well suited for development of therapeutic 
antibodies, however, there are some important problems with using this technique. 
The hybridoma process takes approximately between 6 and 8 months to obtain a 
sufficient amount of mAbs, so its development procedure is very long. On the other 
hand, because of the murine origin of the antibodies, they can trigger the HAMA 
response in the host which could accelerate mAb clearance and undesirable allergic 
reactions upon repeated administration. This issue was resolved by developing anti-
body engineering methods toward producing less immunologic chimeric or human-
ized antibodies. These engineered antibodies were created using murine variable 
regions or CDRs as well as human constant regions aiming to decrease HAMA 
response and maintain target specificity. Currently, fully humanized antibodies are 
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generated in transgenic mice models (e.g. HuMabMouse and XenoMouse) using 
hybridoma technology. For this purpose, the mouse immunoglobulin gene loci have 
been replaced with human loci within the transgenic mouse genome [8].
3.2 Phage display technique
The phage display method is one alternative to traditional hybridoma technol-
ogy for generating monoclonal antibodies. This method was developed in 1985 by 
George P. Smith, who demonstrated that a peptide of interest could be displayed 
on the surface of filamentous phages following inserting the DNA fragment into 
the coat protein gene of phage. Then, a process known as “panning or biopanning” 
is explained by Parmley and Smith; the process describing a selection and affinity 
enrichment in order to isolation of peptide-phage fusions based on their specific 
binding affinity. Finally, phage display technology was used for the first time by 
McCafferty and Winter for generating antigen specific mAbs by creating combina-
torial antibody libraries on filamentous phages [11].
This method involves integration of a gene sequence coding for a particular 
antibody into the DNA sequence of a filamentous bacteriophage leading to the 
expression of interest protein on the surface of the bacteriophage capsid. These 
phage libraries could be generated from healthy donors (creating Naïve librar-
ies) or individuals who carry a particular disease, such as metastatic cancer or 
particular infection, or have been immunized with a particular antigen (creating 
immunized libraries). M13 is a filamentous bacteriophage that is widely used for 
antibody production via phage display. This phage infects Escherichia coli (E. coli) 
strains.
The discovery of smaller recombinant antibody fragments such as Fv (vari-
able region consisting of VH and VL), Fab, single-chain variable domain (scFv), 
and diabodies (bivalent scFvs) has played an important role in the advancement 
of antibody phage display technology [11, 12]. Compared to full antibodies, these 
fragments are more inclined to expression in bacteria. These fragments can be 
cloned into a bacteriophage (next to the coat protein known as PIII protein) using a 
vector. Bacteriophages are then used to infect E. coli to generate a library containing 
approximately 1010 cells. Later, bacteriophage containing the antibody segments 
were secreted from E. coli. These cells can then be isolated and sequenced. This 
technology enables fast and large-scale production of antibodies without animal use 
and it is easy to screen a large diversity of clones. However, it has some drawbacks, 
such as more expensive costs and more difficult techniques [11, 12].
4.  Applications of monoclonal antibodies: therapeutic and diagnostic 
uses
4.1 Therapeutic applications of mAbs in cancer therapy
Monoclonal antibodies could be designed specifically against a target antigen 
found on cancer cells. Several therapeutic mAbs have been approved against differ-
ent cancer types after the discovery of proto-oncogenes and specific tumor antigens 
[13]. In 1994, an antibody named MAB 17-1A was approved against epithelial cell 
surface antigen for identification of adenocarcinomas. It was efficient in reducing 
the mortality and occurrence rate of colorectal cancer [14]. Rituximab, an anti-
CD20 chimeric antibody, was approved in 1997 for treating non-Hodgkin B cell 
lymphoma. Rituximab interacts with CD20 antigen expressed on B cell tumors 
and then eliminates malignant cells through an effective immune response [15]. 
Monoclonal Antibodies
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Ibritumab (Zevalin®), Obinutuzumab (Gazyva®), and Ofatumumab (Arzera®) 
are the other mAbs against CD20 antigen [16].
Epidermal growth factor receptor (EGFR) is another antigen molecule 
expressed on many human cancer cells involved in cancer progression and metas-
tasis. A fully humanized anti-EGFR mAb has been reported to reduce cancer 
growth in-vitro and in-vivo. Cetuximab (Erbitux®, C225), a chimeric IgG1, binds 
to EGFR and induces receptor internalization and degradation. This mAb was 
approved for the treatment of patients with EFFR-expressing metastatic colorectal 
cancer (mCRC). Panitumumab (Vectibix®, Amgen) is a fully human IgG2 against 
EGFR used for the treatment of CRC [17, 18]. Necituzumab (Portrazza®), another 
EGFR-targeting mAb, is a humanized IgG1 indicated for treatment of patients with 
metastatic squamous non-small cell lung cancer [16].
Another well-known humanized mAb, trastuzumab (Herceptin®), has been 
approved for the treatment of breast cancer [19]. Herceptin is an IgG1 mAb that 
binds to HER2 protein expressed on breast tumor cells and can be used to treat 
breast tumors with overexpression of HER2 (about 30% of breast cancer patients) 
[20]. Pertuzumab (Perjeta®) and Ado-trastuzumab emtansine (Kadcyla®) are the 
other humanized IgG1 mAbs targeting HER2 [16].
Immune checkpoint blockade therapy is another antitumor approach. Immune 
checkpoint molecules such as Programmed Cell Death Protein 1 (PD-1) and cyto-
toxic T-lymphocyte-associated protein 4 (CTLA-4) expressed on cancer cells and 
act as inhibitory receptors which result in suppressing immune response against 
tumor cells. Anti-PD1/PD-L1 therapy has been shown promising results to treat a 
variety of cancer types such as lung, liver, blood, and skin cancers [21]. Nivolumab 
(Opdivo®) is a fully human IgG4 mAb against PD-1 approved for the treatment 
of metastatic melanoma, metastatic squamous non-small cell lung cancer, and 
metastatic non-squamous non-small cell lung cancer. Pembrolizumab (Keytruda®) 
is also a humanized IgG4 mAb targeting PD-1 that was approved for melanoma, 
lung cancer, and lymphoma. CTLA4 is another checkpoint molecule that could be 
inhibited by a human IgG1 named Ipilimumab (Yervoy®). CTLA4 plays a critical 
role in inhibition of T cells, especially during the early stages of T cell expansion. 
Therefore, ipilimumab could improve T cell activation and promote immune 
response against tumor [16].
Anti-idiotype mAbs have been considered in cancer therapy because they can 
mimic tumor associated antigens. Idiotype is referred to antigen binding sites in 
the variable domain of an antibody molecule. Anti-idiotype mAbs could mimic 
tumor antigens and may be used as alternate antigens or vaccines for immunization 
against the tumor [22]. ACA125 is a murine anti-idiotype monoclonal antibody that 
mimics the tumor antigen CA125. ACA125 was shown to induce anti-anti-idiotypic 
immune response in the numbers of patients with ovarian cancer associated with 
prolonged survival [22, 23]. Similarly, good results have been shown in patients 
with advanced CRC receiving murine anti-idiotype mAb that mimics an epitope of 
carcinoembryonic antigen (CeaVac) [14, 22]. Another anti-idiotype mAb, TriGem, 
that mimics disialoganglioside GD2 also demonstrated promising results in patients 
with melanoma [24].
Fusion proteins consisting of the Fv region of a mAb and a bacterial toxin are 
also considered as another strategy for cancer therapy which is known as “recom-
binant immunotoxins”. The immunotoxins derived from Pseudomonas entero-
toxin shown an effective response against solid tumors as well as lymphomas and 
leukemias [25].
Radioimmunotherapy using mAbs against cancer cells has also been considered 
as an efficient therapeutic approach. To this end, mAbs could be labeled with 
radioisotopes such as iodine-131 and yttrium-90 to deliver radioisotopes to target 
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cells. Iodine-131 and Yttrium-90 were used in the treatment of Hodgkin’s disease 
and lymphoma [26]. Using radiolabeled mAbs was also shown in cancer diagnosis 
using a diagnostic imaging called immunoscintigraphy [27]. Despite the promising 
results, there are still several obstacles to the mAbs application in cancer therapy, 
such as specific targeting without affecting normal cells as well as resistance the 
tumor cells to drugs [28].
4.2 Therapeutic applications of mAbs in the treatment of autoimmune diseases
Immune system activation in autoimmune diseases or after organ transplanta-
tion could be potentially suppressed by mAbs. Successful therapeutic applications 
of mAbs have been shown in several inflammatory conditions such as psoriasis, 
rheumatoid arthritis (RA), juvenile arthritis, Crohn’s disease, and multiple 
sclerosis, [29].
4.2.1 Anti-TNF monoclonal antibodies
Because of the crucial role in inflammatory responses, TNF-a is considered as 
an important cytokine involved in pathogenesis of several disorders such as RA, 
Crohn’s disease, and spondyloarthritides and, therefore, anti-TNF agents have 
become an efficient approach used in treatment for these diseases. Infliximab 
(Remicade®) is a human chimeric IgG1 anti-TNF antibody that interacts with 
soluble and transmembrane forms of TNF-a resulting in inhibiting proinflam-
matory cascade signaling. Binding infliximab to cells expressing TNF led to cell 
destruction through antibody and CDC [30, 31]. Inhibiting TNF-a could prevent 
the production of proinflammatory cytokines such as IL-1, IL-6, and IL-8 [32]. 
Infliximab was used in 1993 to treat patients with persistent RA. In addition to 
RA, infliximab was approved to treat crohn’s disease, psoriasis, psoriatic arthritis, 
ankylosing spondylitis, and ulcerative colitis [33]. Moreover, infliximab could also 
induce T lymphocyte apoptosis in Crohn’s disease [34]. Remarkable improvement in 
clinical parameters such as improvement of joint swelling, pain, reducing the level 
of inflammatory mediators such as C-reactive protein (CRP) were seen in patients 
with RA after treating with infliximab [31, 33].
In addition to infliximab, several other anti-TNF mAbs have also been approved 
for treating autoimmune disorders. These monoclonal antibodies include adalim-
umab, golimumab, and certolizumab [35]. Adalimumab (Humira®), is a fully human 
IgG1 mAb neutralizing TNF-a and could induce apoptosis in cells expressing TNF 
[36]. Adalimumab is approved for use in RA, ankylosing spondylitis, psoriatic arthri-
tis, juvenile idiopathic arthritis, Crohn’s diseases, ulcerative colitis, and Psoriasis [37]. 
Golimumab (Simponi®), a fully human mAb, has been approved for RA, ankylosing 
spondylitis, psoriatic arthritis, ulcerative colitis, and juvenile idiopathic arthritis [38]. 
Certolizumab (Cimzia®) is a PEGylated Fab fragment approved for the treatment of 
Crohn’s disease, RA, psoriatic arthritis, and ankylosing spondylitis [39].
4.2.2 Anti-IL-1 and anti-IL-1R monoclonal antibodies
The role of the IL-1 family and their receptors are well-known in inducing and 
regulating inflammation in autoimmune disorders [40]. Promising results have 
been shown in patients with autoimmune diseases after using anti-IL-1 mAbs such 
as Canakinumab, or targeting IL-1 receptor such as anakinra [41].
Canakinumab (ACZ885, Ilaris®) is an anti-IL-1β IgG1 mAb neutralizing IL-1β 
resulting in inhibition of inflammation in patients with autoimmune disease. 
Canakinumab was first approved in 2009 for treatment of cryopyrin-associated 
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periodic syndrome (CAPS) [42]. Afterward, this mAb was approved for other 
inflammatory disorders including TNF receptor associated periodic syndrome 
(TRAPS), mevalonate kinase deficiency (MKD), familial Mediterranean fever 
(FMF), and hyperimmunoglobulin D syndrome (HIDS).
Anakinra is an antagonist for IL-1RI which prevents the interaction of IL-1α 
as well as IL-1β to IL-1R1 resulting in reducing inflammatory response and tissue 
damage. Anakinra is currently approved for the treatment of RA and cryopyrin-
associated periodic syndromes [43]. Other anti-IL1 mAbs are also under investi-
gation for clinical use such as Gevokizumab (anti-IL-1β IgG2 mAb), LY2189102 
(anti-IL-1β IgG1 mAb), MABp1 (anti-IL-1α IgG1 mAb), and MEDI-8968 (blocking 
IL-1RI) [41].
4.2.3 Anti-IL-6 and anti-IL-6R monoclonal antibodies
IL-6 is an inflammatory cytokine involved in the initiation or progression of 
immune responses in several autoimmune diseases such as RA. Tocilizumab or atli-
zumab (Actemra® or RoActemra®), is a humanized anti-IL-6 receptor mAb and 
binds to both soluble and membrane-bound IL-6 receptor. Its efficacy is currently 
being explored in the treatment of RA, systemic juvenile idiopathic arthritis in 
children, Castleman’s disease, systemic lupus erythematosus (SLE), juvenile derma-
tomyositis (DM), vasculitis, and juvenile scleroderma [44]. Sarilumab (Kevzara®) 
is another human IgG1 mAb against IL-6 receptor developed for the treatment of 
RA [43]. Sirukimab, olokizuman, and clazakumab are the inhibitors of IL-6 that are 
currently under development for treating inflammatory disorders.
4.2.4 Anti-CD20 monoclonal antibodies
CD20 antigen is a phosphoprotein expressed on B lymphocytes involved in B 
cell proliferation and activation by initiating an intracellular signaling pathway. 
Targeting CD20 by mAbs induces B cell apoptosis and could inhibit B cell function 
through antibody-dependent cell mediated cytotoxicity and complement-depen-
dent cytotoxicity. Rituximab (Rituxan®), a chimeric mAb against CD20 antigen, 
has been first approved for the treatment of lymphomas. Rituximab was approved 
for treating RA in combination with methotrexate, which could improve symptoms 
in patients [45]. Also, promising results have been shown in treating other autoim-
mune diseases including systemic lupus erythematosus [46], dermatomyositis [47], 
severe autoimmune hemolytic anemia [48, 49], refractory immune thrombocyto-
penic purpura [50], Wegener’s granulomatosis [51]. Ocrelizumab (Ocrevus®) is 
another humanized anti-CD20 antibody that targets CD20 molecules on B lympho-
cytes. It was approved for the treatment of the primary progressive form of multiple 
sclerosis. Ofatumumab, a fully human anti-CD20 antibody, has been shown to be 
effective and safe in treating patients with autoimmune diseases. Phase II and III 
trials are ongoing to evaluate the efficiency of ofatumumab in patients with mul-
tiple sclerosis and rheumatoid arthritis, respectively [52, 53].
A phase III trial is ongoing for evaluating a novel glycoengineered chimeric 
anti-CD20 mAb in patients with relapsing forms of multiple sclerosis (RMS). 
Glycoengineering led to increased affinity for FcγRIIIa receptors and enhanced 
ADCC [54].
4.2.5 Other monoclonal antibodies for treating autoimmune diseases
There are several mAbs targeting cytokines or their receptors developed to 
reduce inflammatory response in autoimmune disorders. IL-17 as a major cytokine 
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of Th17 cells, plays crucial roles in immune response against bacterial and fungal 
infections, as well as in the pathogenesis of autoimmune diseases, importantly in 
psoriasis [55]. Secukinumab (Cosentyx®), an IgG1 human mAb, binds to IL-17A 
and is approved for the treatment of psoriasis and ankylosing spondylitis. Another 
mAb against IL-17A, named Ixekizumab (Taltz®) also neutralizes IL-17 and was 
developed for the treatment of moderate to severe plaque psoriasis. Brodalumab 
(Siliq® or Kyntheum®) is a human mAb also approved for plaque psoriasis. It binds 
to the IL-17 receptor and inhibits the related signaling pathway. Brodalumab also 
interacts with IL-17 and prevents its binding to IL-17 receptor [56].
In addition to IL17, a monoclonal antibody targeting IL-23 would be a poten-
tial treatment for plaque psoriasis. IL-23 is also a key proinflammatory cytokine 
playing an important role in Th-17 differentiation and activation. Guselkumab 
(Tremfya®), Risankizumab (SKYRIZI®), and Tildrakizumab (Ilumya®) are 
IgG1 mAbs targeting IL-23 p19 approved for the treatment of patients with plaque 
psoriasis [55].
Targeting adhesion molecules which play an important role in leukocyte activa-
tion, circulation, and localization to inflammatory sites is also considered as an 
efficient therapeutic approach in treating autoimmune diseases [57]. Natalizumab 
(Tysabri®), a humanized mAb against the cell adhesion molecule α4-integrin, was 
the first mAb approved for treatment of MS. Natalizumab prevents the interaction 
of α4-integrin with VCAM-1 expressed on endothelial cells, resulting in the inhibi-
tion of leukocyte migration to the central nervous system. Natalizumab is also used 
for treating Crohn’s disease [53]. Alemtuzumab (Lemtrada®) is a humanized mAb 
against CD52 (or COMPATH1) expressed on lymphocyte, monocytes, and dendritic 
cells. It could destroy CD52-expressing cells by inducing ADCC. Alemtuzumab was 
approved for the treatment of patients with multiple sclerosis and chronic lympho-
cytic leukemia as well as immunomodulation in organ transplantation. Vedolizumab 
(Entyvio®), a humanized mAb against a4b7 integrin, has also been developed for 
treatment of patients with Crohn’s disease and ulcerative colitis [53, 58].
4.3  Therapeutic applications of mAbs in the treatment of graft-versus-host 
disease
Two monoclonal antibodies including OKT3 (a murine IgG2a antibody against 
human CD3) and antibodies against IL-2 receptor (CD25) have been approved to 
reduce allograft rejection [59].
Graft-versus-Host Disease (GVHD) is a complication of bone marrow transplan-
tation causing death in patients. GVHD occurs when alloreactive donor T cells inter-
act with major histocompatibility (MHC) molecules in the host, leading to immune 
system activation and releasing higher amounts of cytokines [60]. Targeting T cells 
before their activation could be effective in inhibiting GVHD. The expression of 
CD25 on T cells is considered as an important step in their alloreactive activation. 
Therefore, mAb therapy using anti-CD25 monoclonal antibody might inhibit T cells 
and could be an effective therapeutic agent [61]. However, the production of anti-
mouse antibodies and HAMA response in the host could affect the effectiveness of 
these mAbs.
Using mAbs for treatment of other complications that occurred post transplan-
tation is also shown. Rituximab, an anti CD20 mAb used for treatment of posttrans-
plant lymphoproliferative disorder [62]. In addition, odulimomab, an anti-LFA1 
mAb, was shown to have a protective function against ischemia–reperfusion injury 
after kidney transplants [62, 63]. Another humanized mAb named Daclizumab 




4.4 Therapeutic applications of mAbs in the treatment of asthma
High serum levels of immunoglobulin E (IgE) plays an important role in the 
pathogenesis of allergic asthma causing bronchial hyperresponsiveness [65, 66]. 
New treatment approaches have been developed to manage disease severity in 
patients with asthma, including using humanized monoclonal antibodies against 
IgE or cytokines involved in initiation or persistence of asthmatic inflammation. 
It has been shown that in patients with moderate to severe allergic asthma, admin-
istration of recombinant humanized anti-IgE antibody could result in decreasing 
serum IgE levels as well as asthma symptoms. These antibodies can exert their 
effects by forming a complex with free IgE resulting in the inhibition of IgE inter-
action with its receptor expressed on mast cells and basophils [66]. Omalizumab 
(Xolair®), a humanized mAb, inhibits IgE binding to its receptor (FcɛR1) and 
showed appropriate efficiency in patients with severe asthma [67].
Targeting IL-4, IL-5, IL-13, IL-9 cytokines could also be an effective approach 
in the treatment of allergic eosinophilic asthma [68]. IL-4 is an important media-
tor for TH2 cell differentiation which acts by binding to its receptor, IL-4 receptor 
(IL-4R), expressed on several types of immune cells. Dupilumab (Dupixent®), a 
monoclonal antibody against IL-4R, was approved for patients with moderate to 
severe asthma [69]. Targeting IL-5 could be effective in reducing asthmatic symp-
toms due to its role in the maturation, activation, and maintenance of eosinophils. 
Mepolizumab (Nucala®), Reslizumab (Cinqair®), and Benralizumab (Fasenra®) 
are mAbs against IL-5 approved for eosinophilic asthma [68]. Mepolizumab and 
Benralizumab block the interaction of soluble IL-5 with its receptor on the eosino-
phils. Benralizumab binds to the IL-5R expressed on the eosinophils and then inhib-
its the IL5R signaling pathway. Besides, this mAb can lead to eosinophils’ apoptosis 
through interaction with FcγRIIIa expressed on the natural killer cells [70]. IL-13 
is a crucial cytokine involved in IgE production from B lymphocytes causing 
smooth muscle contractility in asthma [71]. Lebrikizumab and Tralokinumab are 
mAbs against IL-13 acting by neutralizing IL-13 and inhibiting IL-13 binding to its 
receptor [72–76]. Targeting IL-9 could be effective in inhibiting mast cell activa-
tion. MEDI-528, a humanized IgG1 monoclonal antibody, targets IL-9 and inhibits 
its function in asthma pathogenesis [77]. Other mAbs such as Tezepelumab (anti 
Targeting thymic stromal lymphopoietin or TSLP) and Daclizumab (anti IL-2R α 
chain (CD25)) are also effective in inhibiting the induction of type 2 cytokines (e.g. 
IL-5, IL-4 and IL-13) and inhibiting lymphocyte activation, respectively [78, 79].
4.5  Other therapeutic applications: using mAbs in the treatment of sepsis and 
viral infections
Sepsis is considered as an inflammatory immune response and potentially life-
threatening disorder that occurs in response to an infection. Bacterial infections are 
the important cause of sepsis, but other infections including viral, fungal or proto-
zoan infections can also trigger sepsis [80]. Targeting inflammatory mediators such 
as TNF-α or its receptor could be efficient against inflammatory response. However, 
inhibiting bacterial toxin or important bacterial components such as endotoxin or 
lipid-A (gram-negative bacteria component) may be more effective in the treatment 
of septic shock. The efficiency of two types of mAbs including E5 (XoMA, Berkeley, 
CA), a murine IgM mAb, and HA-1A (Centoxin), a human IgM, have been shown 
in patients with sepsis [81, 82].
Using therapeutic mAbs is also shown in the treatment of viral infections. 
Cytomegalovirus (CMV) could affect immunocompromised individuals, including 
patients with AIDS and those undergoing organ transplants. CMV proteins could 
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be targeted by mAbs [83]. A humanized mAb against gpUL75 (gH), a glycoprotein 
of CMV, could interact with several strains of virus and may be considered as an 
appropriate agent for the treatment of patients with CMV infection [84].
A mAb named Palivizumab has been approved for Respiratory syncytial virus 
(RSV) infection which causes severe lower respiratory tract disorder [85]. Using 
mAbs has also been reported for the treatment of HSV infections.
Currently, several types of monoclonal antibodies have been designed for 
the treatment of patients with coronavirus disease-2019 (COVID-19) [86]. 
Bamlanivimab (LY-CoV555 or LY3819253) is a human IgG1 mAb against the SARS-
CoV-2 spike (S) protein and could block viral entry into human cells [87]. Despite 
the authorization by FDA for emergency use for patients with positive SARS-CoV-2 
viral test, Bamlanivimab has not been approved yet.
4.6 Monoclonal antibodies in the diagnostic assays
High specificity and high affinity binding properties of monoclonal antibodies 
make them effective biological reagents in immunodiagnostic assays. They can be 
used for diagnosis of infectious diseases and detection of certain antigens or in 
serological assessments for detection of antibodies against a certain antigen [88]. 
Monoclonal antibodies are widely used in several immunodiagnostic assays includ-
ing immunohistochemistry (IHC) or immunocytochemistry (ICC), Enzyme-linked 
Immunosorbent Assay (ELISA), western blot, immunodot blot, radio immuno 
assay (RIA), Immunofluorescence (IF), flow cytometry, and microscopy (electron, 
fluorescence, confocal) [89].
In all methods, detection of the specific antigens on the tissue sections, cell sur-
face, or in the homogenized sample needs the interaction between specific mAbs 
and the target antigen. To visualize this interaction, either the primary antibody or 
secondary antibody must be labeled. Totally, the primary antibody is labeled in the 
direct methods (such as direct ELISA, IF, and RIA) in which the antibody directly 
interacts with antigens immobilized on a solid tissue or on a surface [89–91]. In the 
indirect methods, two types of antibodies have been used. The primary antibodies 
are fixed on a surface and could capture antigen of interest, and then secondary 
antibody could interact with this complex. In these methods, the secondary anti-
body is labeled, allowing for signal detection. Various labels could be used, such as 
fluorescent molecules, enzymes, or radioisotopes. Fluorescent labeling requires a 
fluorescence microscope, while using enzymes such as horseradish peroxidase or 
alkaline phosphatase results in producing a colored product after incubation with a 
chromogenic substrate such as diaminobenzidine (DAB) [92–94].
5. Conclusion
The stability and flexibility of antibodies and their effector functions are impor-
tant factors that determine the applicability of immunoglobulins for the development 
of therapeutic mAbs. The majority of the clinically available mAbs are IgG. High 
specificity and high affinity binding properties of monoclonal antibodies make them 
useful biological drugs for the treatment of a variety of disorders including autoim-
munity, malignancies, and asthma. They can be used to diagnose infectious disorders 
and identify specific antigens, as well as in serological tests to detect antibodies 
against specific antigens. In addition, monoclonal antibodies are widely used in 
several immunodiagnostic assays with high sensitivity and specificity. Consequently, 
due to their important functions in both diagnosis and treatment of diseases, mono-
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